Otos’ Post

Your website is more important than you think 💡 Stopwatch Creative work rebranding Mahajan Therapeutics, later led to an acquisition by BayMark Health Services! Learn more on stopwatchcreative.com

Divine Mind Therapeutics LLC recently made a video on the topic of Choices and how certain choices can be responsible for things either going in your favor or not. Check out their video on their socials. https://lnkd.in/ecVmgFcc Here is a snippet

🫀💵Great new day for the team at CorFlow as they announce €44M in new #funding toward their novel, CoFl, diagnostic and drug delivery platform for #microvascular obstruction (MVO). CorFlow’s CoFI system provides physicians with the ability to both detect and delivery therapy to life threatening MVOs in patients suffering acute #coronary events while still in the cath lab. The Series B will fund CorFlow’s MOCA II (MVO with CoFI System Assessment II) pivotal study across the US and Europe validating efficacy to diagnosis MVOs in heart attack patients post stent implementation as well as study for their adaptive therapeutic delivery platform. This latest round was co-led by Broadview Ventures Inc and Panakes Partners alongside 415 Capital, CorFlow’s initial VC investor and largest shareholder. "CorFlow’s breakthrough technology has been designed by clinicians for clinicians and we are excited to support CorFlow's mission to generate robust clinical data in order to get this much needed therapy to the patient as quickly as possible. We also are committed to supporting the emerging field of microvascular disease in general, and this oversubscribed funding round gives us options to apply the technology in new ways, and in new geographies, where patients can benefit.” - Barbara Castellano, Partner at Panakes Partners #medtechmoney #coronarydisease #venturecapital #medicalinnovation The Mullings Group

New partnership announcement coming out of CincyTech portfolio company Enable Injections, Inc.! Enable Injections and Serina Therapeutics, Inc. are teaming up to revolutionize Parkinson's Disease treatment. 🧠💉 Their recent agreement aims to develop SER-252 in combination with enFuse, offering advanced solutions for those battling Parkinson's Disease. 🔍 SER-252, coupled with enFuse technology, promises groundbreaking advancements in Parkinson's treatment. With enhanced delivery methods, this collaboration could significantly improve patients' quality of life. Read more about this game-changing partnership here: https://lnkd.in/e4KYSJdZ #ParkinsonsDisease #MedicalInnovation #HealthcareAdvancements

Elated to share the progress our current project, MUVON (aka MUVON Therapeutics AG) is making with their phase II clinical study (SUISSE MPC2 study (NCT05534269)) ✨   In this phase of the study, measurable data from 10 female patients were included, with a 6-month follow up window, following the injection of the tissue-engineered product into the urethal muscle. We’re happy to hear that the International Data Safety Monitoring Board has recommended the continuation of the study, which means that MUVON is on schedule for the release of the final data and completion of the phase II study scheduled for Q3 2025. 🙌   The study aims to assess the safety and efficacy of MUVON’s Muscle Precursor Cell (MPC)-based #Therapy to treat Stress Urinary Incontinence (#SUI), a condition where there is involuntary leakage of urine during activities that put pressure on the bladder, for example, laughing, coughing, or lifting heavy weights. Such a condition occurs due to weakened #Muscles and #Tissues that support the bladder, preventing the bladder from holding urine during physical stress. More info below ⬇️   #ClinicalStudyProgress #TissueEngineering #BiotechInnovation #InvestorInterest #InvestorSupport #HealthcareAdvancements #InnovativeHealthcare

Proud to see our very own Matt Williams and Guy Checketts featured in The Guardian in a series of articles exploring digital therapeutics and the challenges of bringing them to market. We’re sharing key insights on navigating NHS adoption and other critical hurdles in the journey to success. Read the full articles for expert advice! https://lnkd.in/eeCxgzTd #DigitalHealth #HealthcareInnovation #DTx #TheGuardian

Today, technology isn't just advancing; it’s changing lives in profound ways. At Speranza Therapeutics, we are proud to offer the S.T. Genesis device, helping individuals reclaim their lives by easing opioid withdrawal symptoms. This is more than just a tool—it’s a beacon of hope for patients and healthcare providers. The opportunity to be part of a solution in this critical time gives me hope for the future. Together, we can harness the power of innovation for real, lasting change. Let’s keep pushing boundaries and make a positive impact. Check out the video below to learn more! #innovation #addictionmedicine #recovery #technology #healthcare #hope #change

Vivacelle Bio to Participate in BIO Partnering @ JPM Week 2025 Vivacelle Bio, a late-stage biopharma company developing life-saving treatments for shock and trauma, today announced its participation in BIO Partnering @ JPM Week 2025 in San Francisco, January 13-16. During the event, Vivacelle's management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and clinical development strategy, recent corporate achievements, and anticipated milestones.  KANSAS CITY, Mo., Jan. 9, 2025 /PRNewswire https://lnkd.in/en7HBCge

Need some help with your #mRNA workflow? We can help! 🙌 Innovation in #mRNA therapeutics is on the brink of transforming healthcare. But hey, we know it's not all rainbows and unicorns - the precision and complexity can throw some serious curveballs. But fear not! With our reliable expertise and solutions, we here to be your helping hand. Let’s move forward together. #mRNAtherapeutics #WeAreCytiva

# Only put off until tomorrow what you are willing to die having left undone ## Seize the Opportunity to Grow Your HSA with Fortress Biotech's Recent FDA Approval and Upcoming PDUFA Date! 💪💼🚀 Fortress Biotech, Inc. has recently made significant strides in the healthcare sector, capturing the attention of investors seeking to make the most of their Health Savings Accounts \(HSA\). The company announced that its revolutionary product, Emrosi, designed to treat inflammatory lesions of rosacea in adults, has received FDA approval on November 4, 2024. This approval is a significant milestone for Fortress Biotech, signaling its commitment to delivering innovative solutions that enhance wellness and improve the quality of life for patients suffering from this common skin condition. In addition to the FDA approval for Emrosi, Fortress Biotech has also disclosed an upcoming PDUFA date for cosibelimab, further bolstering investor enthusiasm. Cosibelimab is anticipated to bring new opportunities in the immunotherapy field, potentially revolutionizing treatment options for various medical conditions. While Fortress Biotech's financial results have shown a net loss, it is important to remember that investing in the healthcare industry is a long-term game. By capitalizing on burgeoning healthcare advancements, you have the power to not only grow your HSA but also support breakthrough innovations that can positively impact the lives of countless individuals. Don't let the Fear of Missing Out \(FOMO\) hold you back! Act now and explore the potential of investing in Fortress Biotech, leveraging the growth prospects offered by Emrosi's FDA approval and the upcoming PDUFA date for cosibelimab. Let your HSA flourish by investing in the future of healthcare. #hsa #investing #healthcare #health #family #wellness 📈💰💼💪❤️🏥